Mizuho Securities Maintains Their Buy Rating on Incyte Corp (INCY)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Incyte Corp (INCYResearch Report) today and set a price target of $95.00. The company’s shares closed last Monday at $76.12.

According to TipRanks.com, Goldstein has 0 stars on 0-5 star ranking scale with an average return of -6.8% and a 31.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Arcus Biosciences Inc.

Currently, the analyst consensus on Incyte Corp is a Moderate Buy with an average price target of $94.83, implying a 24.3% upside from current levels. In a report issued on September 30, JMP Securities also maintained a Buy rating on the stock with a $110.00 price target.

See today’s analyst top recommended stocks >>

Based on Incyte Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $105 million. In comparison, last year the company had a net profit of $29.18 million.

Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.